Inhibrx Biosciences, Inc. INBX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Profitability | ||||
| Operating margin | -10,386.5%+155,337pp | -165,724%-153,545pp | -12,178.9%— | |
| Net margin | -10,773.5%-878,492pp | 867,718.5%+881,127pp | -13,408.9%— | |
| EBITDA margin | -10,195.5%+154,386pp | -164,582%-152,469pp | -12,112.8%— | |
| Free cash flow margin | -9,986.5%+88,516pp | -98,503%— | —— | |
| Returns | ||||
| Return on equity | -197.8%-2,158pp | 1,960%+2,435pp | -475.3%— | |
| Return on assets | -85.6%-796pp | 710.3%— | —— | |
| Efficiency | ||||
| Asset turnover | 0×0.0× | 0×— | —— | |
| Liquidity | ||||
| Current ratio | 3.9×0.0× | 3.9×-1.3× | 5.2×— | |
| Quick ratio | 3.9×0.0× | 3.9×-1.3× | 5.2×— | |
| Cash ratio | 3.7×-0.1× | 3.7×-1.2× | 4.9×— | |
| Leverage | ||||
| Debt-to-equity | 13.4×+13.3× | 0.1×-4.8× | 4.8×— | |
| Debt-to-assets | 0.7×+0.7× | 0×-0.6× | 0.7×— | |
| Interest coverage | -11.1×+13.5× | -24.6×-17.7× | -6.9×— | |
| Per Share | ||||
| Book value per share | $0.52-94.2% | $8.92+141% | $3.69— | |
| Valuation | ||||
| Market capitalization | $1.4B+546% | $222.93M-59.5% | $550.08M+54.2% | |
| Enterprise value | $1.42B+1,233% | $78.38M-83.7% | $482.3M— | |
| Price / sales | 1,073.7×— | 1,114.6×+809× | 305.6×— | |
| Price / book | 143.7×+142× | 1.7×-11.0× | 12.6×+6.5× | |
| EV / sales | 870.6×+479× | 391.9×+124× | 267.9×— | |
| Free cash flow yield | -9.5%+68.6pp | -88.4%— | —— | |
| Earnings yield | -9.3%-829pp | 778.5%+822pp | -43.9%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Inhibrx Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Inhibrx Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
